Results 111 to 120 of about 19,221 (177)

Neurotensin and its receptors in the control of glucose homeostasis

Frontiers in Endocrinology, 2012
The pharmacological roles of the neuropeptide neurotensin through its three known receptors are various and complex. Neurotensin is involved in several important biological functions including analgesia and hypothermia in the central nervous system and ...
Jean eMazella, Sophie eBéraud-Dufour, Christelle eDevader, Fabienne eMassa, Thierry eCoppola   +4 more
doaj   +1 more source

iCARDIO Alliance Global Implementation Guidelines for the Management of Obesity 2025

Journal of Cachexia, Sarcopenia and Muscle, Volume 17, Issue 1, February 2026.
ABSTRACT There are a number of guidelines on how to manage obesity, but inconsistencies in healthcare access, varying infrastructure, resource constraints and diverse local practices restrict their global applicability. This underscores the need for universal recommendations that address the unique challenges faced by patients and healthcare providers ...
Stefan D. Anker, Linong Ji, Tammy Kindel, Andrew J. S. Coats, Dike Ojji, Adriana Puente Barragán, Peter Rossing, Shelley Zieroth, Shaaf Ahmad, Shariq Usman, Geeta Appannah, Alison L. Bailey, Ahmed Bennis, Andrea Brandao, Javed Butler, Melanie J. Davies, Lubomira Fabryova, Yuan‐Lin Guo, Hidetaka Itoh, Uday M. Jadhav, Carel W. Le Roux, Fausto J. Pinto, Julio Rosenstock, Banshi Saboo, Hani Sabbour, Mangesh Tiwaskar, Karol E. Watson, Kwang Wei Tham, Fernando Stuardo Wyss, Walter P. Abhayaratna, William T. Abraham, Wael Al Mahmeed, Alessia Argirò, John J. Atherton, Danielle Belardo, Raquel Campuzano, Nandini Chatterjee, Marc‐André Cornier, Sarah Davies, Clemencia de Rueda Panadero, Anastase Dzudie, Ty J. Gluckman, Muhammad Shahzeb Khan, Kamlesh Khunti, Yuri Lopatin, Zhiyi Ma, Okechukwu S. Ogah, Abraham Oomman, Emilio S. Peralta Lopez, Ping Li, Paul Poirier, Julie Redfern, Giuseppe M. C. Rosano, Donna Ryan, Amit Saraf, Sameh Shaheen, Subodh Verma, Stephan von Haehling, Martha Gulati, Naveed Sattar, Jose Luis Zamorano   +60 more
wiley   +1 more source

Stem Cell Secretome Treatment Reduces Adiposity and Improves Glucose Handling During Obesity and Weight Loss in Mice

Obesity, Volume 34, Issue 2, Page 382-393, February 2026.
ABSTRACT Objective In this study, we investigated the effects of a stem cell‐derived secretome product on adiposity and tissue quality and insulin and glucose levels in obese mice and those undergoing dietary weight loss. Methods Following 16 weeks of high fat diet mice received acute (4 weeks) biweekly intramuscular injections with vehicle or ...
Zachary J. Fennel, Anu S. Kurian, Paul‐Emile Bourrant, Chad M. Skiles, Robert J. Castro, Elena M. Yee, Scott A. Greilach, Hans S. Keirstead, Gabriel Nistor, Nicole C. Berchtold, Thomas E. Lane, Micah J. Drummond   +11 more
wiley   +1 more source

Recent clinical and pharmacological advancements of incretin-based therapy and the effects of incretin on physiology

Journal of Diabetology
A novel therapeutic target for diabetes mellitus is incretin-based therapies, glucagon-like peptide-1, and glucose-dependent insulinotropic polypeptides are released from the gastrointestinal (GI) tract and act on beta cells of pancreatic islets by ...
Bhaskar Pal, Moitreyee Chattopadhyay
doaj   +1 more source

The Effect of Porcine Orexin a on Glucose-Dependent Insulinotropic Polypeptide Plasma Concentrations in Pigs

European Journal of Inflammation, 2010
The orexigenic system was discovered in 1998. It consists of two neuropeptides, Orexin A and Orexin B. Researchers have focused more on Orexin A, since its intracerebroventricular injection into the lateral ventricle of the rat's brain causes an increase
P. Papakonstantinou, N. Tziris, D. Kapoukranidou, A. Gotzamani-Psarrakou, C.H.R. Tsonidis, M.N. Patsikas, G. Papazoglou   +6 more
doaj   +1 more source

Metabolic Outcomes in Patients With Type 2 Diabetes Prescribed Incretin‐Based Therapy and Referred or Not to a Weight Management Clinic: A Single‐Center Retrospective Analyses

Obesity Science &Practice, Volume 12, Issue 1, February 2026.
ABSTRACT Background Incretin therapies yield strong metabolic improvements, but whether adding a weight‐management (WM) clinic confers additional benefit beyond pharmacotherapy alone in routine care is unclear. Objective Evaluate whether referral to WM clinic, alongside standard diabetes care, provides additional benefit for adults with type 2 diabetes
Kathleen M. Robinson, Stephanie H. Rodriguez, Cyril Pedagarla, Patrick Ten Eyck, Marcelo Correia, Ayotunde Dokun   +5 more
wiley   +1 more source

Characterisation of Glucose-Dependent Insulinotropic Polypeptide Receptor Antagonists in Rodent Pancreatic Beta Cells and Mice

Clinical Medicine Insights: Endocrinology and Diabetes, 2019
Hypersecretion and alterations in the biological activity of the incretin hormone, glucose-dependent insulinotropic polypeptide (GIP), have been postulated as contributing factors in the development of obesity-related diabetes.
RA Perry, SL Craig, MT Ng, VA Gault, PR Flatt, N Irwin   +5 more
doaj   +1 more source

Development of the Weight and Emotions Scale (WES)

Obesity Science &Practice, Volume 12, Issue 1, February 2026.
ABSTRACT Objective Obesity and overweight are associated with significant psychosocial burden. Existing patient‐reported outcome (PRO) measures only assess a subset of emotion‐related concepts that are relevant to individuals living with these conditions.
Chisom Kanu, Miriam Kimel, Iris Goetz, Lisa M. Neff, Kristina S. Boye, Marissa Stefan, Jessica Jordan   +6 more
wiley   +1 more source

Características de acción de las exendinas sobre el transporte y metabolismo hepático y muscular de la glucosa, en estado normal y diabético tipo 2 [PDF]

, 2008
Tesis doctoral inédita. Universidad Autónoma de Madrid, Facultad de Ciencias, Departamento de Biología.
Arnés Pérez, Luis
core   +1 more source

Preclinical Modeling and Simulation to Explore the Tissue/Plasma Exposure and Pharmacodynamic Effect of Vildagliptin in Diabetes Treatment

CPT: Pharmacometrics &Systems Pharmacology, Volume 15, Issue 2, February 2026.
ABSTRACT Vildagliptin (VDG) is a dipeptidyl‐peptidase‐4 (DPP‐4) inhibitor used for type 2 diabetes (T2DM) treatment. Viewing to improve VDG treatment, a population pharmacokinetic (popPK) model was built to describe drug plasma, free liver and muscle concentrations determined by microdialysis in healthy and diabetic animals following 50 mg/kg i.v ...
Bruna Bernar Dias, Laura Ben Olivo, Bibiana Verlindo de Araújo   +2 more
wiley   +1 more source